Publications
Peer-Reviewed Publication
Roberts, S.B., Hirschfield, G.M., Worobetz, L.J., Vincent, C., Flemming, J.A., Cheung, a., Qumosani, K, Swain, M., Grbic, D., Ko, H.h., Peltekian, K., Selzner, N., Abrahamyan, L., Aziz, B., Lytvyak, E., Tirona, K., Gulamhusein, A.F., Janssen H.L.A., Montano-Loza, A.J.., Mason, A. L., Hansen, B.E.2022. Ethnicity disease severity, and survival in Canadian patients with primary biliary cholangitis. HEPATOLOGY.
Roberts, S., Worobetz, L., Vincent, C., Flemming, J., Tsien, C., Qumosani, K., Swain, M., Grbic, D., Ko, H.H., Peltekian, K., Selzner, N., Abrahamyan, L., Saini, M., Tirona, K., Aziz, B., Lytvyak, E., Montano-Loza, A., Hirschfield, G., Janssen, H., Gulamhusein, A., Mason A.L., & Hansen, B. (2021, July). Patterns of biochemical response during long-term UDCA treatment in patients with primary biliary cholangitis: association with liver transplant-free survival. In JOURNAL OF HEPATOLOGY (Vol. 75, pp. S228-S229). RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS: ELSEVIER.
Roberts SB, Ismail M, Kanagalingam G, Mason AL, Swain MG, Vincent C, Yoshida EM, Tsien C, Flemming JA, Janssen HL, Hirschfield GM., Hansen BE, Gulamhusein AF. Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatology communications. 2020 Sep;4(9):1332-45. doi: 10.1002/hep4.1518.
Abstracts and Posters
Roberts, S.B., Worobetz, L.J., Vincent, C., Flemming, J.A., Tsien, C., Qumosani, K., Swain, M. Grbic, D., Ko, H.H., Peltekian, K., Selzner, N., Abrahamyan, L., Saini, M., Tirona, K., Aziz, B., Lytvyak, E., Mason, A.L., Hansen, B.E., on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Patterns of biochemical response during long-term UDCA treatment in patients with Primary Biliary Cholangitis: association with liver-transplant-free survival. Journal of Hepatology 2021;
75(Suppl 2): S435.
Plagiannakos, C., Roberts, S.B., Saini, M., Vincent, C., Worobetz, L.J., Flemming, J.A., Tsien, C., Qumosani, K, Gulamhusein, A.F., Janssen, H.L.A., Mason, A., Hirschfield, G.M., Hansen, B.E. on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Younger age is associated with lower self-reported quality of life among patients with autoimmune liver disease during Canada’s response to the COVID-19 pandemic. Journal of Hepatology 2021; 75(Suppl 2): S228-S229.
Roberts, S.B., Worobetz, L.J., Vincent, C., Flemming, J.A., Tsien, C., Qumosani, K., Swain, M. Grbic, D., Ko, H.H., Peltekian, K., Selzner, N., Abrahamyan, L., Saini, M., Tirona, K., Aziz, B., Lytvyak, E., Mason, A.L., Hansen, B.E., on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Patterns of biochemical response during long-term UDCA treatment in patients with Primary Biliary Cholangitis: association with liver-transplant-free survival. Canadian Liver Journal 2021; 4(2), 182-183. https://doi.org/10.3138/canlivj.4.2.abst
Plagiannakos, C., Roberts, S.B., Saini, M., Vincent, C., Worobetz, L.J., Flemming, J.A., Tsien, C., Qumosani, K, Gulamhusein, A.F., Janssen, H.L.A., Mason, A., Hirschfield, G.M., Hansen, B.E. on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Younger age is associated with lower self-reported quality of life among patients with autoimmune liver disease during Canada’s response to the COVID-19 pandemic. Canadian Liver Journal 2021; 4(2), 126-127.
https://doi.org/10.3138/canlivj.4.2.abst
Aziz B, Roberts SB, Lytvyak E, Montano-Loza AJ, Hansen BE, Mason A, on behalf of the Canadian Network for Autoimmune Liver (CaNAL) disease. Elevated Neutrophil/Lymphocyte Ratio (NLR) one-year post-diagnosis is associated with decreased liver transplant-free and overall survival in PBC. Hepatology 2020;72(Suppl 1): 743A-744A.
Roberts SB, Aziz B, Plagiannakos C, Saini M, Ko H, Tsien C, Flemming JA, Worobetz LJ, Vincent C, Gulamhusein AF, Janssen HLA, Hirschfield GM, Mason AL, Hansen BE, on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Quality of Life among Patients with Primary Biliary Cholangitis during Canada’s State of Emergency Response to COVID-19. Hepatology 2020;72(Suppl 1):297A-298A.
Plagiannakos C, Roberts SB, Saini M, Vincent C, Worobetz LJ, Flemming JA, Tsien C, Gulamhusein AF, Janssen HLA, Mason A, Hirschfield GM, Hansen BE, on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Differences in self-reported quality of life among patients with Autoimmune Hepatitis and Primary Biliary Cholangitis during Canada’s State of Emergency response to COVID-19. Hepatology 2020;72(Suppl 1):270A-271A.
Plagiannakos C, Hirschfield GM, Roberts SB, Gulamhusein AF, Saini M, Tirona K, Mason A, Worobetz LJ, Flemming JA, Tsien C, Janssen HLA, Hansen BE, Montano-Loza AJ, on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Factors Associated with ALT Normalisation in Patients with Autoimmune Hepatitis: A Canadian Multi-Site Cohort study. Hepatology 2020;72(Suppl 1):745A-746A.
Roberts SB, Hirschfield GM, Vincent C, Worobetz LJ, Flemming JA, Janssen HLA, Gulamhusein AF, Mason A, Hansen BE, on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher pbc-40 quality of life scores. Journal of Hepatology 2020;73(Suppl 1):S488-S489.
Roberts SB, Hirschfield GM, Vincent C, Worobetz LJ, Flemming, JA, Janssen HLA, Gulamhusein AF, Mason A, Hansen BE, on behalf of the Canadian Network for Autoimmune Liver disease (CaNAL). Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher pbc-40 quality of life scores. Canadian Liver Journal 2020;3(1):127.
Roberts SB. (presenter), Ismail M, Kanagalingam G, Mason A, Swain M, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF. Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of real-world experience. Sheila Sherlock Liver Research Day 2018 Oral Presentation, Toronto, Ontario, Canada, September 26, 2019.
Roberts SB, Ismail M, Kanagalingam G, Mason A, Swain M, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF. Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of real-world experience. University of Toronto Gastrointestinal Research Day 2019 Poster Presentation (Best Clinical Abstract Award), Toronto, Ontario, Canada, June 10, 2019.
Roberts SB, Gulamhusein AF, Ismail M, Mason A, Swain MG, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hansen BE, Hirschfield GM. Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry. University of Toronto Gastrointestinal Research Day 2019 Poster Presentation, Toronto, Ontario, Canada, June 10, 2019.
Roberts SB, Ismail M, Kanagalingam G, Mason A, Swain M, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF. Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of real-world experience. Canadian Liver Journal 2019;2(2):101.
Roberts SB, Gulamhusein AF, Ismail M, Mason A, Swain MG, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hansen BE, Hirschfield GM. Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry. Canadian Liver Journal 2019;2(2):101-102.
Roberts SB, Ismail M, Kanagalingam G, Mason A, Swain M, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hirschfield GM, Hansen BE, Gulamhusein AF. Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of real-world experience. Journal of Hepatology 2019;70(1):e409.
Roberts SB, Gulamhusein AF, Ismail M, Mason A, Swain MG, Vincent C, Yoshida E, Tsien C, Flemming JA, Janssen HLA, Hansen BE, Hirschfield GM. Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry. Journal of Hepatology 2019;70(1):e408-e409.